Basic Information
DiNAQOR AG's Mission and Gene Therapy Innovations for Heart DiseaseDiNAQOR AG is dedicated to developing gene therapy solutions aimed at transforming the lives of patients with heart disease. Its novel and innovative gene therapy platform focuses on providing advanced treatments for hereditary cardiomyopathies, which are myocardial disorders that can lead to heart failure.Founded in April 2019 by a team of top pharmaceutical and biotechnology executives and academics with deep expertise in cardiology and gene therapy, DiNAQOR AG has established strategic partnerships with leading institutions and companies such as Lonza and University Medical Center Hamburg-Eppendorf. These collaborations aim to enhance their cardiac gene therapy platforms and product pipelines. Headquartered in Pfäffikon, Switzerland, DiNAQOR AG also has offices in London, UK, and Boston, Massachusetts.